The completion of this heavily dilutive private placement removes the overhang of an uncertain closing, but the ~$1.18/share price represents a significant discount to any prior trading levels. Monitor for use of proceeds and any subsequent operational updates that could justify the dilution.
Price Chart
Executive Summary
Indaptus Therapeutics completed its previously announced private placement on October 16, 2026, issuing 20,338,974 shares for aggregate gross proceeds of approximately $24.0 million. This filing confirms the closing of the capital raise first disclosed on September 8, 2026, with the outside date extended from September 29 to October 16.
Key Facts
- Completed private placement of 20,338,974 shares of common stock
- Aggregate gross proceeds of approximately $24.0 million
- Shares issued at approximately $1.18 per share (based on $24.0M / 20,338,974 shares)
- Offering was first disclosed on September 8, 2026, with outside date extended to October 16, 2026
- CEO Junyi Dai signed the filing
Financial Impact
Dilutive equity offering raising $24.0M in gross proceeds; 20.3M new shares issued
Risk Factors
- Massive dilution: 20.3M new shares added to a pre-offering float that was likely very small
- Low offering price (~$1.18/share) signals distressed financing conditions
- No disclosed use of proceeds beyond general corporate purposes
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-047770 |
| Document: 0001493152-26-047770-index-headers.html | 0001493152-26-047770 |
| Document: 0001493152-26-047770-index.html | 0001493152-26-047770 |
| Document: 0001493152-26-047770.txt | 0001493152-26-047770 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.34 (+5.70%) |
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.34 (+5.70%) |
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.34 (+5.70%) |
Oct 21, 2026 5d ago | SC 13D/A | $2.99 | awaiting T+60 | — | $3.34 (+11.71%) |
Oct 20, 2026 6d ago | 8-K | $3.16 | awaiting T+60 | — | $3.34 (−5.70%) |
Sep 30, 2026 26d ago | 8-K | $2.30 | awaiting T+60 | — | $3.34 (+45.22%) |
Sep 9, 2026 6w ago | 8-K | $2.56 | awaiting T+60 | — | $3.34 (−30.47%) |
Sep 4, 2026 7w ago | 424B5 | $1.85 | awaiting T+60 | — | $3.34 (−80.54%) |
Sep 1, 2026 7w ago | 8-K | $1.13 | awaiting T+60 | — | $3.34 (−195.58%) |
Aug 26, 2026 8w ago | EFFECT | $1.14 | awaiting T+60 | — | $3.34 (−192.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers